Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.8 USD | -1.30% | -5.42% | -21.72% |
Financials (USD)
Sales 2024 * | 29.08M | Sales 2025 * | 2.68M | Capitalization | 849M |
---|---|---|---|---|---|
Net income 2024 * | -199M | Net income 2025 * | -297M | EV / Sales 2024 * | 11 x |
Net cash position 2024 * | 528M | Net cash position 2025 * | 356M | EV / Sales 2025 * | 184 x |
P/E ratio 2024 * |
-4.25
x | P/E ratio 2025 * |
-3.23
x | Employees | 124 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.28% |
Latest transcript on Zentalis Pharmaceuticals, Inc.
1 day | -0.38% | ||
1 week | -4.70% | ||
Current month | +8.05% | ||
1 month | -5.98% | ||
3 months | -13.53% | ||
6 months | +5.29% | ||
Current year | -21.12% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 55 | 20-06-30 | |
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Mark Lackner
CTO | Chief Tech/Sci/R&D Officer | 56 | 22-10-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cam Gallagher
FOU | Founder | 54 | 14-12-22 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 23-05-07 |
Karan Takhar
BRD | Director/Board Member | 32 | 17-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.09% | 0 M€ | 0.00% | - | |
0.07% | 2 M€ | -.--% | ||
0.04% | 1,487 M€ | +9.08% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 11.86 | -0.88% | 60 189 |
24-05-16 | 11.96 | -0.13% | 370,523 |
24-05-15 | 11.98 | +2.61% | 589,889 |
24-05-14 | 11.67 | -0.68% | 504,707 |
24-05-13 | 11.75 | -6.30% | 665,954 |
Delayed Quote Nasdaq, May 17, 2024 at 10:08 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.12% | 849M | |
+8.63% | 114B | |
+10.59% | 104B | |
-12.73% | 22.41B | |
-0.58% | 22.28B | |
-5.80% | 19.07B | |
-37.36% | 18B | |
-5.54% | 17.89B | |
+6.98% | 14.28B | |
+36.60% | 12.55B |
- Stock Market
- Equities
- ZNTL Stock